ImmunArray

Diagnostic Tests for Autoimmune Diseases

Health Tech & Life Sciences

Acquired (Inactive) by Salveo Diagnostics on Aug 2019 - ceased to operate

Company Overview

Snapshot

Founded in January 2006 by Irun Cohen, ImmunArray operated with 1–10 employees and raised a total of $15.5 million across five funding rounds from four investors. The company was acquired by Salveo Diagnostics in August 2019.

Business overview

ImmunArray develops in-vitro diagnostic tests utilizing its iCHIP microarray technology platform. This technology mines immune system repertoires to provide insights into an individual's immune profile, detecting global patterns of auto-antibodies from a blood sample via proprietary antigen sets. The company's products support a personalized medicine approach, focusing on diagnosis, prognosis, and therapeutic guidance for autoimmune diseases and improving transplantation medicine. ImmunArray also develops markers for traumatic brain injury, serving the healthcare and laboratory sectors with a focus on biotechnology and diagnostics.

Strategic signal

In November 2018, ImmunArray appointed a new CEO, while the former CEO transitioned to lead a spin-off venture. This leadership change signaled a strategic realignment for the company, potentially indicating a renewed focus on its core diagnostic offerings or a strategic move to spin out non-core assets ahead of its acquisition.

Company Intelligence Q&A

What is ImmunArray's primary focus?: ImmunArray develops in-vitro diagnostic tests based on its iCHIP microarray technology platform, primarily for autoimmune diseases and transplantation medicine.
When was ImmunArray acquired?: ImmunArray was acquired by Salveo Diagnostics in August 2019 and subsequently ceased operations.
What is the core technology behind ImmunArray's products?: ImmunArray's core technology is the iCHIP platform, which measures auto-antibody repertoires from a blood sample using microarray technology to provide diagnostic and prognostic profiles.
Did ImmunArray receive any grants?: ImmunArray received a grant from the BIRD Foundation in January 2007 and another grant in January 2014.
What was a significant leadership change at ImmunArray?: In November 2018, ImmunArray hired a new CEO, while the former CEO moved to lead a spin-off venture.

External links

ImmunArray — full profile (machine-readable)

ImmunArray (IAL) is developing in-vitro diagnostic tests based on its iCHIP microarray technology platform. The products support a personalized medicine approach, and IAL's first product family will provide tests for diagnosis, prognosis, and therapeutic guidance for autoimmune diseases and improving transplantation medicine. ImmunArray's iCHIP technology mines the information stored in immune system repertoires in order to shed light on an individual's specific immune profile. The iCHIP platform measures an individual's auto-antibody repertoires in a drop of blood using microarray technology. Global patterns of antibodies are detected via proprietary sets of antigens and analyzed to provide a highly specific diagnostic and prognostic profile of the individual. The company is also developing a set of markers of traumatic brain injury, both as standalone acute care tests and as iCHIP components to monitor for the emergence of chronic sequelae of traumatic brain injury. ImmunArray holds an exclusive, worldwide license from the Weizmann Institute of Science for the iCHIP technology. The company also has licenses from Brigham and Women's Hospital and Johns Hopkins University for additional components of the technology.

Facts
Name	ImmunArray
One-liner	Diagnostic Tests for Autoimmune Diseases
Type	Startup
Primary sector	Health Tech & Life Sciences
Founded	2006
Employees	1-10
Employees (exact)	6
HQ / location	Rehovot, HaMada 12, Rehovot, Israel, Center District
Product stage	Released
Crunchbase	immunarray
IL Registrar	513778233

Facts

Name

ImmunArray

One-liner

Diagnostic Tests for Autoimmune Diseases

Type

Startup

Primary sector

Health Tech & Life Sciences

Founded

2006

Employees

1-10

Employees (exact)

HQ / location

Rehovot, HaMada 12, Rehovot, Israel, Center District

Product stage

Released

Crunchbase

immunarray

IL Registrar

513778233

Classification
Sectors	Health Tech & Life Sciences, Pharma & Medical Biotechnology, Test Diagnostics & Screening
Core technology	Biologicals, Genes
Target customers	Healthcare & Life Sciences, Healthcare, Providers, Laboratories
Business models	B2B
Tags	detection, hospitals, antibodies, diagnostics, blood-test, medical-technologies, biotechnology, laboratories, academia, degenerative-diseases, personalized-medicine, autoimmune-diseases

Classification

Sectors

Health Tech & Life Sciences, Pharma & Medical Biotechnology, Test Diagnostics & Screening

Core technology

Biologicals, Genes

Target customers

Healthcare & Life Sciences, Healthcare, Providers, Laboratories

Business models

B2B

Date	Round	Amount	Investors
Jul 2016	B Round	$10M	Exigent Capital Group
Jul 2007	Undisclosed Round	Undisclosed	RAD BioMed
Jan 2014	nonequity	$300K
Jan 2007	nonequity	Undisclosed	BIRD Foundation
Apr 2013	A Round	$5.2M	Lazlow Tauber Foundation, Virginia Life Sciences Investments (VLSI)

Name	Role	Founder
Donna Edmonds	Chairman
Susan Evans	CEO
Irun Cohen	Co-founder & Senior Advisor	yes

Date	Source	Summary
Aug 14, 2019	www.360dx.com	Salveo Dx Merges With ImmunArray, Nudge
Nov 2, 2018	www.richmond.com	Biotech company ImmunArray hires new CEO, while former CEO leads spin-off venture
Jan 28, 2018	www.immunarray.com	Account Suspended
Jul 10, 2017	www.businesswire.com	ImmunArray Enters Partnership with Kindstar Global
Jul 13, 2016	www.globes.co.il	Molecular diagnostic co ImmunArray raises $10m
Jul 21, 2007	www.israel21c.org	Israel's Immunarray develops simple early-stage blood test for lung cancer

ImmunArray

Company Overview

Snapshot

Business overview

Strategic signal

Company Intelligence Q&A

External links

Generate Slim Page